Welcome to the UPF Digital Repository

Estimated population prevalence of heart failure with reduced ejection fraction in Spain, according to DAPA-HF Study Criteria

Show simple item record

dc.contributor.author Camps-Vilaró, Anna
dc.contributor.author Delgado-Jiménez, Juan F.
dc.contributor.author Farré López, Núria
dc.contributor.author Tizón-Marcos, Helena
dc.contributor.author Álvarez-García, Jesus
dc.contributor.author Cinca, Juan
dc.contributor.author Dégano, Irene R.
dc.contributor.author Marrugat de la Iglesia, Jaume
dc.date.accessioned 2020-10-01T06:28:09Z
dc.date.available 2020-10-01T06:28:09Z
dc.date.issued 2020
dc.identifier.citation Camps-Vilaró A, Delgado-Jiménez JF, Farré N, Tizón-Marcos H, Álvarez-García J, Cinca J. et al. Estimated population prevalence of heart failure with reduced ejection fraction in Spain, according to DAPA-HF Study Criteria. J Clin Med. 2020 Jul 3; 9(7):2089. DOI: 10.3390/jcm9072089
dc.identifier.issn 2077-0383
dc.identifier.uri http://hdl.handle.net/10230/45361
dc.description.abstract Heart failure (HF) is one of the main causes of morbidity, mortality, and high healthcare costs. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduced cardiovascular mortality and hospitalization for HF compared to placebo in patients with chronic HF, and reduced ejection fraction (EF) in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study. Our aim was to estimate the number of patients with DAPA-HF characteristics in Spain. Our literature review identified epidemiological studies whose objective was to quantify the prevalence of HF and its comorbidities in Spain. We estimated the prevalence of HF with reduced EF, of New York Heart Association (NYHA) functional class II-IV, and with a glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m². In this population, we analysed the prevalence of diabetes using data from the REDINSCOR (Spanish Network for Heart Failure) registry. Our estimations indicate there are 594,684 patients ≥45 years old with HF in Spain (2.6% of this population age group), of which 52.4%, 84.0%, and 93.9% have reduced EF, are NYHA II-IV, and have a GFR ≥ 30 mL/min/1.73 m², respectively. By our calculations, approximately 245,789 Spanish patients would meet the DAPA-HF patient profile, and therefore could benefit from the protective cardiovascular effects of dapagliflozin.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher MDPI
dc.rights Copyright © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Estimated population prevalence of heart failure with reduced ejection fraction in Spain, according to DAPA-HF Study Criteria
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3390/jcm9072089
dc.subject.keyword Cardiovascular disease
dc.subject.keyword Cardiovascular therapy
dc.subject.keyword Dapagliflozin
dc.subject.keyword Epidemiology
dc.subject.keyword Heart failure
dc.subject.keyword Prevalence
dc.subject.keyword Reduced ejection fraction
dc.subject.keyword Sodium-glucose cotransporter-2 inhibitor
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking